Barry is a Managing Director at Frankel Group LLC (FG), which he founded in March of 1993. Following nearly 20 years in the life science industry, Barry saw an opportunity to pull together a unique team of experienced professionals from suppliers, providers, banking and consulting to capitalize on the emerging new business models required and provide financially grounded, creative strategic solutions to the pharmaceutical, biotechnology, device/diagnostic and life science service sectors. He has worked collaboratively with Geller Biopharm on several projects over the past 3 years.
Since the founding of Frankel Group, Barry has advised and managed a diverse range of engagements spanning most therapeutic areas, including business strategies and business model evolution; R&D portfolio planning and technology platform assessments; the identification and valuation of acquisition, licensing and alliance candidates; market entry and geographic expansion commercialization strategies; and new company formation and division spinoff creation and funding. Clients have spanned multinational and specialty pharmaceutical companies, emerging bio/pharmaceutical firms, device and diagnostic companies, industry intermediaries including CRO's and CSO's, and a range of private equity and banking firms.
In addition, Barry has led FG's expansion into the transactions area. This effort initiated with an asset management advisory role in equity4life, AG, a Switzerland based life science venture capital firm. Currently, FG has evolved its transaction strategy to work with a select group of banking partners in individual company formation, funding and post funding advisory services.
Prior to Frankel Group, Barry was President of SJ Weinstein Associates, a health care marketing strategy and communications firm, where he formulated marketing strategies for some of the leading life science companies. His earlier experience included Strategic Planning for Pfizer Pharmaceuticals, as well as Senior Marketing positions at Pfizer in the anti-infective, multisource pharmaceutical and diagnostic markets. In addition, Barry was a Senior Investment Research Officer for life science investments at Citibank. Barry serves on the Board of Directors of Inspiration Biopharmaceuticals and Molecular Insight Pharmaceticals; is a member of the Pfizer Specialty Products Advisory Board; and serves as an advisor to the Rutgers Center for Innovation and Emerging Technology (CIVET). Barry holds a Masters in Business Administration with Distinction from The Wharton School of The University of Pennsylvania, and a Bachelors of Science Summa Cum Laude in Engineering from Rutgers University.